GLG LLC’s Galmed Pharmaceuticals GLMD Stock Holding History

GLG LLC’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-836	Closed	-$1.36M	–	463
2017 Q3	$1.36M	Buy	836 +330	+65%	+$457K	0.09%	248
2017 Q2	$565K	Buy	+506	New	+$477K	0.03%	393

Other funds holding GLMD

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GLG LLC's GLMD Position: Q4 2017 in Review

GLG LLC sold out of Galmed Pharmaceuticals (GLMD) in Q4 2017, closing a stake of 836 shares — an estimated $1.36M sold.

GLG LLC first reported a position in GLMD in Q2 2017 and held it in 2 quarters. The position peaked at $1.36M in Q3 2017. 19 funds tracked by Wall St. Rank hold GLMD as of Q4 2017.

GLG LLC reported no remaining Galmed Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
GLG LLC sold 836 Galmed Pharmaceuticals shares in Q4 2017, an estimated $1.36M.
GLG LLC first reported a position in Galmed Pharmaceuticals in Q2 2017 and held it in 2 quarters.
GLG LLC's Galmed Pharmaceuticals position peaked at $1.36M in Q3 2017.
19 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2017.

Based on GLG LLC's 13F filing for Q4 2017, filed 14 Feb 2018.